PFC
CRNX

Phocas Financial Corp’s Crinetics Pharmaceuticals CRNX Stock Holding History

Phocas Financial Corp’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,877
Closed -$2.51M – 159
2025
Q4 		$2.51M Sell
53,877
-138
-0.3% -$6.14K 0.33% 106
2025
Q3 		$2.25M Buy
+54,015
New +$1.73M 0.29% 108

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Phocas Financial Corp's CRNX Position: Q1 2026 in Review

Phocas Financial Corp sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 53,877 shares — an estimated $2.51M sold.

Phocas Financial Corp first reported a position in CRNX in Q3 2025 and held it in 2 quarters. The position peaked at $2.51M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Phocas Financial Corp reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Phocas Financial Corp sold 53,877 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.51M.
  • Phocas Financial Corp first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Phocas Financial Corp's Crinetics Pharmaceuticals position peaked at $2.51M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Phocas Financial Corp's 13F filing for Q1 2026, filed 1 May 2026.